Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 18 | 2025 | 1723 | 2.460 |
Why?
|
| Aromatase Inhibitors | 6 | 2025 | 19 | 1.750 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2025 | 307 | 1.700 |
Why?
|
| Nitriles | 7 | 2023 | 81 | 1.340 |
Why?
|
| Triazoles | 7 | 2023 | 102 | 1.300 |
Why?
|
| Estrogens | 7 | 2023 | 203 | 1.160 |
Why?
|
| Cell Line, Tumor | 21 | 2025 | 2676 | 0.930 |
Why?
|
| Pterocarpans | 6 | 2024 | 25 | 0.890 |
Why?
|
| Endocrine Disruptors | 3 | 2012 | 44 | 0.740 |
Why?
|
| Sesquiterpenes | 4 | 2025 | 38 | 0.680 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 105 | 0.660 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2025 | 968 | 0.660 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 1019 | 0.630 |
Why?
|
| MicroRNAs | 4 | 2013 | 518 | 0.610 |
Why?
|
| Estrogen Receptor alpha | 8 | 2025 | 121 | 0.530 |
Why?
|
| Proteomics | 2 | 2021 | 378 | 0.470 |
Why?
|
| Cell Proliferation | 11 | 2025 | 1455 | 0.470 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 1596 | 0.440 |
Why?
|
| Cell Movement | 3 | 2025 | 655 | 0.430 |
Why?
|
| Receptors, Estrogen | 6 | 2025 | 183 | 0.370 |
Why?
|
| Allyl Compounds | 2 | 2024 | 55 | 0.370 |
Why?
|
| Sulfides | 2 | 2024 | 78 | 0.370 |
Why?
|
| DDT | 1 | 2012 | 15 | 0.370 |
Why?
|
| Mammary Neoplasms, Experimental | 4 | 2020 | 69 | 0.370 |
Why?
|
| Humans | 31 | 2025 | 43102 | 0.360 |
Why?
|
| Female | 21 | 2025 | 24698 | 0.350 |
Why?
|
| Apoptosis | 4 | 2025 | 1568 | 0.340 |
Why?
|
| Phenols | 1 | 2012 | 107 | 0.340 |
Why?
|
| Disease | 1 | 2010 | 21 | 0.320 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2025 | 47 | 0.320 |
Why?
|
| Phytoestrogens | 2 | 2024 | 39 | 0.290 |
Why?
|
| Signal Transduction | 6 | 2021 | 2157 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 154 | 0.270 |
Why?
|
| Pueraria | 1 | 2025 | 4 | 0.230 |
Why?
|
| Focal Adhesions | 1 | 2025 | 16 | 0.230 |
Why?
|
| Reactive Oxygen Species | 3 | 2025 | 532 | 0.230 |
Why?
|
| Paracrine Communication | 1 | 2025 | 18 | 0.220 |
Why?
|
| Aromatase | 4 | 2022 | 20 | 0.220 |
Why?
|
| Isoflavones | 1 | 2025 | 132 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 347 | 0.210 |
Why?
|
| Garlic | 1 | 2024 | 31 | 0.210 |
Why?
|
| Mice | 9 | 2025 | 6644 | 0.200 |
Why?
|
| Cyclin B1 | 1 | 2023 | 18 | 0.200 |
Why?
|
| Precancerous Conditions | 1 | 2024 | 83 | 0.200 |
Why?
|
| Exosomes | 1 | 2025 | 126 | 0.190 |
Why?
|
| Transcription, Genetic | 4 | 2014 | 592 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2023 | 137 | 0.190 |
Why?
|
| Estradiol | 5 | 2012 | 268 | 0.190 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 40 | 0.170 |
Why?
|
| Animals | 11 | 2025 | 16992 | 0.170 |
Why?
|
| Receptors, CXCR4 | 2 | 2011 | 74 | 0.170 |
Why?
|
| Breast | 1 | 2021 | 139 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 257 | 0.160 |
Why?
|
| Organ Culture Techniques | 1 | 2020 | 101 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 241 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 101 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 179 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 3 | 2025 | 196 | 0.150 |
Why?
|
| Mice, Nude | 3 | 2015 | 408 | 0.150 |
Why?
|
| Cells, Cultured | 3 | 2020 | 1621 | 0.140 |
Why?
|
| Epithelial Cells | 1 | 2021 | 434 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 526 | 0.130 |
Why?
|
| Estrogen Antagonists | 3 | 2010 | 30 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 159 | 0.110 |
Why?
|
| Cell Division | 2 | 2014 | 311 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2014 | 43 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2013 | 883 | 0.100 |
Why?
|
| Cell Shape | 1 | 2013 | 42 | 0.100 |
Why?
|
| rho-Associated Kinases | 1 | 2013 | 36 | 0.100 |
Why?
|
| Chalcone | 1 | 2013 | 5 | 0.100 |
Why?
|
| Mesoderm | 1 | 2013 | 73 | 0.100 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 34 | 0.100 |
Why?
|
| Vimentin | 1 | 2013 | 44 | 0.100 |
Why?
|
| Amides | 1 | 2013 | 71 | 0.090 |
Why?
|
| Pyridines | 1 | 2013 | 139 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 81 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 290 | 0.090 |
Why?
|
| Carcinoma | 1 | 2012 | 108 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 108 | 0.090 |
Why?
|
| Benzhydryl Compounds | 1 | 2012 | 50 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 105 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2011 | 32 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 228 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 134 | 0.090 |
Why?
|
| Reproduction | 1 | 2011 | 94 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2015 | 735 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 1070 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2010 | 19 | 0.080 |
Why?
|
| Receptors, Estradiol | 1 | 2010 | 2 | 0.080 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 39 | 0.080 |
Why?
|
| Cell Survival | 3 | 2025 | 945 | 0.080 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2009 | 19 | 0.080 |
Why?
|
| Terpenes | 1 | 2009 | 30 | 0.080 |
Why?
|
| Environmental Pollutants | 1 | 2011 | 201 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 77 | 0.070 |
Why?
|
| Flavonols | 1 | 2008 | 19 | 0.070 |
Why?
|
| Fermentation | 1 | 2008 | 39 | 0.070 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2009 | 72 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2025 | 299 | 0.070 |
Why?
|
| Molecular Structure | 2 | 2025 | 570 | 0.070 |
Why?
|
| Mice, SCID | 3 | 2013 | 158 | 0.060 |
Why?
|
| Androgens | 1 | 2006 | 106 | 0.060 |
Why?
|
| Spheroids, Cellular | 1 | 2025 | 37 | 0.060 |
Why?
|
| Aspergillus | 1 | 2024 | 14 | 0.060 |
Why?
|
| Models, Molecular | 3 | 2014 | 876 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 220 | 0.050 |
Why?
|
| DNA Polymerase beta | 1 | 2021 | 14 | 0.040 |
Why?
|
| Bromodeoxyuridine | 1 | 2021 | 25 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2024 | 302 | 0.040 |
Why?
|
| DNA Damage | 1 | 2024 | 356 | 0.040 |
Why?
|
| Benzo(a)pyrene | 1 | 2021 | 128 | 0.040 |
Why?
|
| Antioxidants | 1 | 2024 | 443 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2021 | 346 | 0.040 |
Why?
|
| Stereoisomerism | 2 | 2010 | 169 | 0.040 |
Why?
|
| Transfection | 2 | 2012 | 532 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 704 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2024 | 1003 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 458 | 0.030 |
Why?
|
| Casein Kinase II | 1 | 2015 | 17 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 116 | 0.030 |
Why?
|
| Androstenedione | 2 | 2006 | 19 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 31 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 84 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2012 | 13 | 0.020 |
Why?
|
| Serine | 1 | 2012 | 79 | 0.020 |
Why?
|
| Benzylamines | 1 | 2011 | 7 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 98 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 310 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2011 | 23 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2005 | 508 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 652 | 0.020 |
Why?
|
| Response Elements | 1 | 2010 | 55 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 455 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 219 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 129 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 173 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 237 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 986 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2009 | 69 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 416 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2008 | 109 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2009 | 92 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 127 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 671 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 1177 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 934 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 43 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2006 | 28 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 667 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 152 | 0.010 |
Why?
|
| Receptors, Androgen | 1 | 2006 | 144 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 712 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 436 | 0.010 |
Why?
|
| Choriocarcinoma | 1 | 1998 | 2 | 0.010 |
Why?
|
| Microsomes | 1 | 1998 | 55 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 294 | 0.010 |
Why?
|
| Placenta | 1 | 1998 | 117 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1998 | 281 | 0.010 |
Why?
|
| Base Sequence | 1 | 1998 | 983 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1998 | 1271 | 0.010 |
Why?
|